Hydroxyzine

CHEMBL896 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
374.9 g/mol
LogP
3.7
Phase
4

This first-generation antihistamine has anxiolytic, antipruritic, and sedative properties and is used to treat anxiety, itching from allergic conditions, and nausea. It works by blocking histamine H1 receptors and also affects other neurotransmitter systems in the brain. It does not carry the risk of dependence seen with benzodiazepines.

Khối lượng phân tử

374,9000 g/mol

LogP

3,70

TPSA

35,90 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1

InChI

InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2

Molecular Formula

C21H27ClN2O2

HBD / HBA

1 / 4

Liên kết có thể quay

8

Nguyên tử nặng

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This first-generation antihistamine has anxiolytic, antipruritic, and sedative properties and is used to treat anxiety, itching from allergic conditions, and nausea. It works by blocking histamine H1 receptors and also affects other neurotransmitter systems in the brain. It does not carry the risk of dependence seen with benzodiazepines.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Hydroxyzine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL896. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3658. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.